AIMLogo.jpg
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amplitude, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPL
March 07, 2024 17:32 ET | The Rosen Law Firm PA
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Amplitude, Inc. (NASDAQ: AMPL) between September 21, 2021 and...
AIM CEO Corner
AIM ImmunoTech Announces Launch of CEO Corner Platform
March 07, 2024 08:45 ET | AIM ImmunoTech Inc.
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future...
GeoVax.png
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
March 06, 2024 09:00 ET | GeoVax, Inc.
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
July 30, 2021 - ROSEN LOGO.jpg
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX
February 27, 2024 19:49 ET | The Rosen Law Firm PA
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
logo.png
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
February 21, 2024 08:00 ET | BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIVI
February 09, 2024 19:45 ET | The Rosen Law Firm PA
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and...
AIM ImmunoTech Inc.
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
February 08, 2024 08:50 ET | AIM ImmunoTech Inc.
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
invivyd-logo.jpg
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024 16:02 ET | Invivyd
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
January 31, 2024 05:00 ET | AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...